The only SC induction data for an IL-23 inhibitor show statistically significant and clinically meaningful improvements across clinical and endoscopic measures versus placebo, consistent with IV ...
TREMFYA ® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA ® achieved significant rates of ...
The FDA approved a subcutaneous (SC) induction regimen of guselkumab (Tremfya, Johnson & Johnson) for adults with moderately to severely active ulcerative colitis (UC). Guselkumab is the first and ...
(RTTNews) - Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy in adults with ...
Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life Two hundred two patients with low–tumor burden FL were randomly assigned to the ...
"The Week 12 results from the ASTRO study build on data from the QUASAR study demonstrating that both guselkumab SC and IV induction achieved clinically differentiated results in patients with ...
"Historically, IL-23 inhibitors have required IV infusions at the start of therapy, which can create barriers to starting treatment or be burdensome for some patients and clinicians," said David T.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback